Vanda Schizophrenia Drug Patentable, Fed. Circ. Says

Law360 (April 13, 2018, 11:17 PM EDT) -- The Federal Circuit on Friday upheld a patent covering Vanda Pharmaceuticals Inc.’s schizophrenia drug Fanapt, finding it met the U.S. Supreme Court’s Mayo standard by outlining a specific method of using natural phenomena for treatment.

A three-judge panel ruled 2-1 that U.S. Patent Number 8,586,610 covers the use of a patient’s genotype to tailor dosage, but it specifically tells doctors how to harness that relationship and use it in treatments rather than just describing the natural factors themselves.

The Mayo decision requires courts to look at...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals


Case Number

16-2707

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

September 26, 2016


Case Title

Vanda Pharmaceuticals Inc. v. Roxane Laboratories Inc.


Case Number

16-2708

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Question)

Date Filed

September 26, 2016

Law Firms

Companies

Government Agencies

Patents

Judge Analytics

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.